Samsung Bioepis’ Trastuzumab Biosimilar Is Third Cleared By FDA – But The Market Hasn’t Formed Yet

 
• By Dean Rudge
Korea
Incheon-based Samsung Bioepis faces a wait to roll out its second biosimilar • Source: Shutterstock

More from Biosimilars

More from Products